Aurobindo Pharma has announced plans to acquire a 26% equity stake in Swarnaakshu Solar Power as part of its strategy to secure captive renewable energy for its operations.
The proposed investment is aimed at developing a solar power project that will supply electricity for Aurobindo Pharma’s internal consumption, enabling the company to optimize energy costs and enhance sustainability across its manufacturing facilities.
The acquisition structure aligns with India’s regulatory framework for captive power generation, which requires a minimum 26% ownership stake to qualify for associated benefits, including reduced power procurement costs through open access mechanisms.
The transaction is expected to be completed by June 30, subject to the receipt of necessary regulatory approvals and fulfillment of customary conditions.
This development reflects the increasing adoption of captive renewable energy solutions by energy-intensive industries in India, particularly as companies seek to improve cost efficiency, reduce exposure to grid tariff volatility, and align with evolving environmental, social, and governance (ESG) standards.
The move also highlights a broader industry trend, with corporates increasingly investing in renewable energy assets to support long-term operational sustainability and energy security.
Discover more from SolarQuarter
Subscribe to get the latest posts sent to your email.
